CDK9 and cancer: Intensive research in the cancer field has unraveled the role of BET proteins in NF-κB pathway regulation, demonstrating that BRD4 binding to acetylated lysine-310 of RelA is essential for recruiting BRD4 and CDK9 to the promoters of specific NF-κB target genes [90–93].